|
1
|
Hoffman HT, Porter K, Karnell LH, Cooper
JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A and Robinson RA:
Laryngeal cancer in the United States: changes in demographics,
patterns of care and survival. Laryngoscope. 116(Suppl 111): 1–13.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jaseviciene L, Gurevicius R, Obelenis V,
Cicenas S and Juozulynas A: Trends in laryngeal cancer incidence in
Lithuania: A future perspective. Int J Occup Med Environ Health.
17:473–477. 2004.
|
|
4
|
Almadori G, Bussu F, Cadoni G, Galli J,
Paludetti G and Maurizi M: Molecular markers in laryngeal squamous
cell carcinoma: Towards an integrated clinicobiological approach.
Eur J Cancer. 41:683–693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsuzaki J, Torigoe T, Hirohashi Y,
Tamura Y, Asanuma H, Nakazawa E, Saka E, Yasuda K, Takahashi S and
Sato N: Expression of ECRG4 is associated with lower proliferative
potential of esophageal cancer cells. Pathol Int. 63:391–397. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yue CM, Deng DJ, Bi MX, Guo LP and Lu SH:
Expression of ECRG4, a novel esophageal cancer-related gene,
downregulated by CpG island hypermethylation in human esophageal
squamous cell carcinoma. World J Gastroenterol. 9:1174–1178.
2003.PubMed/NCBI
|
|
7
|
Sabatier R, Finetti P, Adelaide J, Guille
A, Borg JP, Chaffanet M, Lane L, Birnbaum D and Bertucci F:
Down-regulation of ECRG4, a candidate tumor suppressor gene, in
human breast cancer. PLoS One. 6:e276562011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mori Y, Ishiguro H, Kuwabara Y, Kimura M,
Mitsui A, Kurehara H, Mori R, Tomoda K, Ogawa R, Katada T, et al:
Expression of ECRG4 is an independent prognostic factor for poor
survival in patients with esophageal squamous cell carcinoma. Oncol
Rep. 18:981–985. 2007.PubMed/NCBI
|
|
9
|
Vanaja DK, Ehrich M, Van den Boom D,
Cheville JC, Karnes RJ, Tindall DJ, Cantor CR and Young CY:
Hypermethylation of genes for diagnosis and risk stratification of
prostate cancer. Cancer Invest. 27:549–560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Götze S, Feldhaus V, Traska T, Wolter M,
Reifenberger G, Tannapfel A, Kuhnen C, Martin D, Müller O and
Sievers S: ECRG4 is a candidate tumor suppressor gene frequently
hypermethylated in colorectal carcinoma and glioma. BMC Cancer.
9:4472009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li LW, Yu XY, Yang Y, Zhang CP, Guo LP and
Lu SH: Expression of esophageal cancer related gene 4 (ECRG4), a
novel tumor suppressor gene, in esophageal cancer and its
inhibitory effect on the tumor growth in vitro and in vivo. Int J
Cancer. 125:1505–1513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li W, Liu X, Zhang B, Qi D, Zhang L, Jin Y
and Yang H: Overexpression of candidate tumor suppressor ECRG4
inhibits glioma proliferation and invasion. J Exp Clin Cancer Res.
29:892010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gonzalez AM, Podvin S, Lin SY, Miller MC,
Botfield H, Leadbeater WE, Roberton A, Dang X, Knowling SE,
Cardenas-Galindo E, et al: Ecrg4 expression and its product augurin
in the choroid plexus: impact on fetal brain development,
cerebrospinal fluid homeostasis and neuroprogenitor cell response
to CNS injury. Fluids Barriers CNS. 8:62011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li L, Zhang C, Li X, Lu S and Zhou Y: The
candidate tumor suppressor gene ECRG4 inhibits cancer cells
migration and invasion in esophageal carcinoma. J Exp Clin Cancer
Res. 29:1332010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu T, Xiao D and Zhang X: ECRG4 inhibits
growth and invasiveness of squamous cell carcinoma of the head and
neck in vitro and in vivo. Oncol Lett. 5:1921–1926. 2013.PubMed/NCBI
|
|
16
|
Jiang CP, Wu BH, Wang BQ, Fu MY, Yang M,
Zhou Y and Liu F: Overexpression of ECRG4 enhances chemosensitivity
to 5-fluorouracil in the human gastric cancer SGC-7901 cell line.
Tumour Biol. 34:2269–2273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Hsiao YC, Hsieh YS, Kuo WH, Chiou HL, Yang
SF, Chiang WL and Chu SC: The tumor-growth inhibitory activity of
flavanone and 2′-OH flavanone in vitro and in vivo through
induction of cell cycle arrest and suppression of cyclins and CDKs.
J Biomed Sci. 14:107–119. 2007. View Article : Google Scholar
|
|
19
|
Ayyagari VN and Brard L: Bithionol
inhibits ovarian cancer cell growth in vitro-studies on
mechanism(s) of action. BMC Cancer. 14:612014. View Article : Google Scholar
|
|
20
|
He L, Lu N, Dai Q, Zhao Y, Zhao L, Wang H,
Li Z, You Q and Guo Q: Wogonin induced G1 cell cycle arrest by
regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in
human colorectal cancer carcinoma cells. Toxicology. 312:36–47.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gross A, Jockel J, Wei MC and Korsmeyer
SJ: Enforced dimerization of BAX results in its translocation,
mitochondrial dysfunction and apoptosis. EMBO J. 17:3878–3885.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang D, Chen MB, Wang LQ, Yang L, Liu CY
and Lu PH: Bcl-2 expression predicts sensitivity to chemotherapy in
breast cancer: A systematic review and meta-analysis. J Exp Clin
Cancer Res. 32:1052013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moldoveanu T, Follis AV, Kriwacki RW and
Green DR: Many players in BCL-2 family affairs. Trends Biochem Sci.
39:101–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar
|
|
26
|
Hall C, Troutman SM, Price DK, Figg WD and
Kang MH: Bcl-2 family of proteins as therapeutic targets in
genitourinary neoplasms. Clin Genitourin Cancer. 11:10–19. 2013.
View Article : Google Scholar
|
|
27
|
Barillé-Nion S, Bah N, Véquaud E and Juin
P: Regulation of cancer cell survival by BCL2 family members upon
prolonged mitotic arrest: opportunities for anticancer therapy.
Anticancer Res. 32:4225–4233. 2012.PubMed/NCBI
|
|
28
|
Thornberry NA and Lazebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cryns V and Yuan J: Proteases to die for.
Genes Dev. 12:1551–1570. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Visconti R and D'Adamio L: Functional
cloning of genes regulating apoptosis in neuronal cells. Methods
Mol Biol. 399:125–131. 2007. View Article : Google Scholar
|
|
31
|
Kuribayashi K, Mayes PA and El-Deiry WS:
What are caspases 3 and 7 doing upstream of the mitochondria?
Cancer Biol Ther. 5:763–765. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lockshin RA: Programmed cell death:
History and future of a concept. J Soc Biol. 199:169–173. 2005.In
French. View Article : Google Scholar
|
